Abstract
In the past decade, studies of the markers expressed on the surface of malignant lymphocytes from patients with lymphoma and leukemia have greatly expanded our knowledge and understanding of these disorders. In addition, the results obtained have allowed individual cases to be categorized to prognostic groups, thus influencing the choice of therapy. These studies should now be considered routine in the evaluation of patients with lymphoid leukemias and lymphomas.